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Background: Limited therapeutic options are available for patients with treatment-refractory major depression who
do not respond to routinely available therapies. Vagus nerve stimulation showed adjunctive antidepressant effect in
chronic treatment resistant depression, even though available studies rarely exceed 2-year follow up.
We report a naturalistic 5-year follow up of five patients who received VNS implant for resistant depression (3 patients
with major depressive disorder and 2 with bipolar disorder).
Methods: Response was defined as a reduction of the 17-item HDRS total score ≥50% with respect to baseline, remission
as a score ≤7.
Results: Response and remission rates were both 40% (2/5) after 1 year, and 60% (3/5) at 5 years. Two patients withdrew
from the study because of side effects or inefficacy of stimulation.
Conclusions: Our case series showed that long-term VNS may be effective in reducing severity of depression in a small
but significant minority of patients, although two patients had stimulation terminated because of adverse effects and/or
refusal to continue the study.
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Major Depressive Episode (MDE) is a clinical condition
affecting about 350 million people worldwide, carries a
high morbidity and mortality and imposes significant
costs on patients, their families, caregivers, employers,
and insurance payers [1].
Despite considerable efforts made over the past de-
cades, there are a large proportion of patients who still
do not respond to currently available treatments [2,3].
Up to 50% of subjects with a MDE who receive an anti-
depressant treatment do not respond satisfactorily to the
first trial and another 50% of them do not fully respond
to a second antidepressant medication [4,5]. Further-
more, patients often show relapses despite treatment
with conventional medication [6].
There is not a general consensus on how many unsuc-
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unless otherwise stated.resistant depression (TRD), and there are several ways of
staging this condition [7-10]. Despite the lack of a unique
definition, TRD can be defined as the absence of response
to at least two antidepressant trials given in succession at
adequate doses and duration in compliant subjects [2].
Rates of TRD range from 2-3% [4] to 30% [11] and vary ac-
cording to the threshold of unsuccessful trials. Treatment-
resistant depression (TRD) remains however a significant
clinical challenge, irrespective of the definition used.
Vagus Nerve Stimulation (VNS) is currently approved
both in Europe and in the USA as an adjunctive long-
term treatment of chronic (actual episode ≥2 years) or
recurrent depression for patients aged 18 years or older
who are experiencing a MDE (both unipolar and bipolar)
and have not had a sufficient response to four or more
adequate antidepressant treatments [12].
VNS therapy® (Cyberonics, Inc, Houston, TX, USA) con-
sists in implanting a generator in the left chest and con-
necting it to the left vagus nerve with a bipolar lead [13].
After generally 2 weeks from surgery, a wand connected to
a hand-held computer activates the device telemetrically.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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vagus nerve; the electrical signals are in turn processed in
the nucleus tractus solitarius and relayed to various regions
of the brain to provide relief of depressive symptoms
through mechanisms not yet fully understood [14].
In recent years, several studies have been performed
examining VNS efficacy in MDEs, and reviews are
already available on several clinical and experimental is-
sues concerning VNS in TRD [15,16]. VNS appears to
be effective acutely in a small but significant proportion
of patients (15.2-57%); moreover, response rates increase
from 3 months to 1 or 2 years [5,17-34].
The time course for the clinical response to VNS sug-
gests that when clinical improvement occurs, it requires
weeks or months to become evident. As such, VNS may
prove more useful as a long-term maintenance therapy
for chronic depression rather than for acute stabilization
of an episode.
The effectiveness of long-term VNS in clinical practice
remains, however, to be determined; the question of
whether VNS is helpful to non-research, treatment-
seeking patients is still open. Moreover, there is a lack of
knowledge regarding long-term follow-up of patients who
underwent VNS therapy: available data do not exceed
2 years, except a case report of a 38-year old woman with
a six-year follow-up [35] and a case series recently pub-
lished with 7 patients who were re-evaluated 48–60
months after surgery [36].
The aim of the present paper is to present data of a
naturalistic 5-year follow-up of patients who received
VNS as an adjunctive treatment for resistant depression.
Methods
Participants
Participants were recruited consecutively from January
2007 to May 2008 among subjects referred to the Mood
and Anxiety Disorders Unit of the Department of Neuro-
science, University of Turin (Italy); this is a tertiary referral
centre located within the University Hospital and special-
ized in the treatment of patients with Mood Disorders.
The aims of the study as well as study procedures were
thoroughly explained to potential participants who gave
written consent before participation. The study design was
reviewed and approved by the local ethics committee
(Comitato Etico Interaziendale A.O.U. Città della Salute e
della Scienza di Torino - A.O. Ordine Mauriziano - A.S.L.
TO1).
To be enrolled in the study, patients fulfilled the fol-
lowing inclusion criteria: a) a current Major Depressive
Episode, chronic (actual episode ≥2 years) or recurrent
(history of at least 4 lifetime MDEs), according to the
Structured Clinical Interview for Axis I Disorders
(SCID-I/P – DSM IV TR) [37]; b) 18 years of age or
older; c) during the current MDE, failure to respond to atleast two adequate trials of antidepressant treatments; d) a
minimum total score of 20 on the HDRS; and e) stable psy-
chopharmacological medication for at least 4 weeks before
baseline. We defined non-responder a patient who failed to
show a reduction of the 17-item HDRS total score ≥50%
with respect to the beginning of the pharmacological trial.
We considered an adequate antidepressant trial, according
to Sackeim [2], a full-dosage antidepressant given for at
least 4 weeks. We also required that patients took two anti-
depressants of different pharmacological classes.
Exclusion criteria were: 1) past or current presence of
psychotic features; 2) suicide attempt requiring medical
treatment within the previous twelve months; 3) history
of schizophrenia, schizoaffective disorder or rapid cyc-
ling bipolar disorder; 4) severe Axis II disorders (such as
borderline or antisocial); 5) alcohol or substance de-
pendence within the previous twelve months or abuse of
a substance other than nicotine during the previous six
months; 6) diagnosis or signs of delirium, dementia, or
amnestic and other cognitive disorders; 7) previous head
injuries, cardiac or neurological diseases, and surgical
implantation-related risks.
All patients were on antidepressants (with or without
mood-stabilizers depending on the diagnosis of MDD or
BD), which were not withdrawn after surgery. Throughout
the follow-up period, the dosage of antidepressant medica-
tions was adjusted according to clinical condition, while
no change of type of antidepressant treatment or mood-
stabilizer was performed during the first year after surgery.Clinical assessment
Unmasked clinical outcome measures included the 17-
item Hamilton Rating Scale for Depression (HDRS-17),
the Montgomery-Asberg Depression Rating Scale
(MADRS), and the Clinical Global Impressions-Severity
of Illness (CGI-S) scale. These measurements were ob-
tained at pre-treatment (baseline), at post-surgery
(2 weeks after implantation), every three months for the
first two years and then annually. During the first
12 months, a self-report measure of quality of life was
also administered: the Medical Outcomes Study 36-Item
Short-Form Health Survey (SF-36). The SF-36 contains
8 scales for assessing physical functioning, role limita-
tions due to physical health, bodily pain, general health,
vitality, social functioning, role limitations due to emo-
tional problems, and mental health. Summary scales in-
clude a physical composite and a mental composite that
are expressed as t scores (mean = 50, SD = 10).
Response was defined as a reduction of the 17-item
HDRS total score ≥50% with respect to baseline, remis-
sion as a score ≤7.
In addition, tolerability and side effects were recorded.
Adverse events were defined as events occurring on or
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signs or symptoms at baseline and/or worsening in se-
verity or frequency. Presence of mania was monitored
using the Young Mania Rating Scale (YMRS): a score of
12 was used as the threshold for the diagnosis of mania.
Operative procedure
The device component consists of a pulse generator with
a lithium battery and a lead wire with two helical elec-
trodes and a tethering anchor. Under operating micro-
scope the helical electrodes and the anchor tether coil
were wrapped around the left cervical vagus nerve and a
strain relief bend of lead to provide slack during move-
ment of the neck was created. The lead connector pin
was attached to a generator situated subcutaneously in
the left thoracic region. The electrical connections of the
whole device were then checked with a system diagnos-
tic performed with the wand and programming com-
puter. During the electro-diagnostic test the pulse
generator delivered 1 mA output current at 20 Hz with
a pulse width of 500 μsec and measured the impedance.
At this moment the heart rate was monitored to high-
light a possible bradycardia. The pulse generator was
then inserted into the subcutaneous pocket and the two
wounds closed in anatomical layers using absorbable su-
ture and paying attention to a good cosmetic result. The
generator was switched off for two weeks postoperatively
to allow postsurgical edema to resolve.
Statistical analysis
Subjects’ characteristics were summarized as mean and
SD for continuous variables and frequency and percent-
age for categorical variables. A repeated measures
ANOVA was performed on total scores of the HDRS,
MADRS and CGI-S scales before (baseline, surgery) and
after 3, 6, 9 and 12 months from VNS implant.
Results
One hundred-fifty-nine subjects were interviewed
through telephone in order to assess eligibility criteria
for inclusion into the study; of them, 39 were asked to
present for a face-to-face clinical interview. Thirty-three
patients were excluded because of not having a current
Major Depressive Episode (N = 7), not having a chronic
(actual episode ≥2 years) or recurrent (history of at least
4 lifetime MDEs) disorder (N = 20), having a medical ill-
ness that contraindicated surgery (N = 4), or having a
current Substance Use Disorder (N = 2). One additional
patient, fulfilling eligibility criteria, first accepted to
undergo surgical procedure, and then refused after the
screening visit.
A total of five patients met the inclusion criteria and
had the VNS generator implanted. The mean ± SD age
of the patients was 56.6 ± 7.3 years (range, 48–66 years).Three patients had a Major Depressive Disorder (60.0%)
and the remaining two patients had a Bipolar Disorder
(one BD type I and one BD type II). Socio-demographic
and clinical data are summarized in Table 1. Concerning
the duration of the current MDE, three patients fulfilled
DSM-IV criteria for chronic (>2 years) major depression
(all three had a diagnosis of unipolar major depression).
Pre-implant history of the two BD patients was carefully
recorded by means of direct interview, family members’
interview (when available) and medical records review.
The first patient (Figure 1) had a history of BD type I
with onset at age 26; he had more than 10 lifetime
MDEs, with 8 admissions to psychiatric wards and 2 sui-
cide attempts during previous episodes. Despite being
on mood stabilizer (valproic acid), during the last two
years preceding VNS implant he showed 3 MDEs (not
considering the current one) without (hypo) manic epi-
sodes, but with intervals between depressive episodes
lasting less than 3 months. Treatments with adjunctive
lamotrigine or quetiapine did not result in stable remis-
sion; adjunctive antidepressants in the current episode
did not resolve depressive symptomatology. The second
patient (Figure 2) had BD type II, with onset at age 36.
He also had more than 10 lifetime MDEs, a history of 1
prior suicide attempt, and had, during the last two years
prior to VNS implant, 2 long-lasting MDEs (not consid-
ering the current one). He spent, during the last two
years prior to surgery, a total of 5 months only without a
MDE (although without complete remission), despite be-
ing treated with valproic acid, quetiapine, lamotrigine,
and four different antidepressants (two of them during
the current MDE). No hypomanic episodes were re-
corded in the last two years.
All patients had the VNS generator implanted but for
the long-term follow-up, four patients (80.0%) were eva-
luable at 24 months and three (60.0%) were evaluable at
60 months. Two patients withdrew from the study: one
subject (Figure 3), whose depression slightly improved
(HDRS-17: 14), withdrew after 18 months because of
side effects judged by the patient as intolerable (hoarse-
ness, sore throat and neck pain), and had the VNS gen-
erator switched off. The other (Figure 2) withdrew after
12 months because symptoms remained unchanged
(HDRS-17: 21); although the clinician in charge of that
patient clearly advised him that VNS efficacy sometimes
is evident after 12 months of treatment, he was unwill-
ing to attend follow-up assessments and dropped out
from the study.
Table 2 shows results of the repeated measures ANOVA
on the total scores of the HDRS, MADRS, CGI-S and SF-
36 scales (all not statistically significant). Figures 1, 2, 3, 4
and 5 show individual scores for each patient and stimula-
tion parameters, as patients had different outcomes over
the 5-year follow-up. According to the HDRS-17, 2 patients
Table 1 Socio-demographic and clinical characteristics of patients included
Sample (N = 5)
Actual age (years) (Mean ± SD) 56.6 ± 7.3
Gender: males, N (%) 2 (40.0)
Educational level (years) (Mean ± SD) 13.4 ± 5.3
Marital status: married, N (%) 2 (40.0)
Currently working, N (%) 4 (80.0)
Age at onset (years) (Mean ± SD) 30.6 ± 4.2
Duration of illness (years) (Mean ± SD) 26.8 ± 5.5
Duration of current MDE (months), (Mean ± SD) 18.4 ± 14.0
Familial history for psychiatric disorders, N (%) 3 (60.0)
Diagnosis, N (%)
Major depressive disorder 3 (60.0)
Bipolar disorder 2 (40.0)
Number of medications at the time of the implant, (Mean ± SD) 3.0 ± 1.4
Number of antidepressant treatments received before the implant, (Mean ± SD) 8.4 ± 2.7
Number of antidepressant classes received before the implant, (Mean ± SD) 3.6 ± 0.9
Number of MDEs before the implant, (Mean ± SD) 9.4 ± 4.9
Number of hospitalizations before the implant, (Mean ± SD) 7.0 ± 2.4
Number of patients with a history of suicidal attempts before implant, N (%) 3 (60.0)
Prior ECT, N (%) 1 (20.0)
MDE: Major Depressive Episode; ECT: ElectroConvulsive Therapy.
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VNS treatment (patients 2 and 4). At 2 years, the three pa-
tients still on treatment were all responders and remitters.
Two of the three patients who were followed-up for 5 years
had one depressive recurrence during the 4th year and the
third subject showed no recurrences for the whole period.Figure 1 HDRS, MADRS and CGI-S scores across time for Patient 4 (m
Obsessive-Compulsive Personality Disorders).Table 3 summarizes the rates of adverse events (AEs)
after VNS implant and during the follow-up period.
With regard to tolerability, patients reported common
side effects traditionally observed in previous clinical
studies. The only side effect related to the surgical pro-
cedure was neck pain located at the level of the surgicalale, 57 years, Bipolar Disorder type I, comorbid Avoidant and
Figure 2 HDRS, MADRS and CGI-S scores across time for Patient 5 (male, 61 years, Bipolar Disorder type II, no comorbid diagnoses).
Figure 3 HDRS, MADRS and CGI-S scores across time for Patient 3 (female, 48 years, Major Depressive Disorder, chronic MDE, no
comorbid diagnoses).
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Table 2 Outcome measures for Intent-to-Treat sample in the first 12 months (N = 5)
Baseline (surgery) 3 months 6 months 9 months 12 months Repeated measures ANOVA
Variable Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) F p
HDRS-17 23.0 (±2.0) 14.8 (±6.9) 15.2 (±8.6) 15.0 (±9.5) 14.6 (±8.7) 1.120 .382
MADRS 31.4 (±5.6) 18.8 (±9.9) 19.6 (±13.1) 19.2 (±14.5) 18.8 (±13.3) 1.496 .250
CGI-S 5.6 (±0.5) 4.0 (±1.6) 4.2 (±1.1) 3.6 (±2.1) 3.4 (±2.3) 2.429 .090
SF-36 physical summary 42.7 (±7.4) 45.8 (±2.9) 46.3 (±7.1) 43.9 (±2.7) 46.6 (±4.4) .416 .794
SF-36 mental summary 25.5 (±17.2) 31.7 (±20.4) 31.3 (±15.2) 26.6 (±11.1) 31.7 (±18.4) .245 .909
HDRS-17: 17-item Hamilton Depression Rating Scale; MADRS: Montgomery Asberg Depression Rating Scale; CGI-S: Clinical Global Impression – Severity of Illness.
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implant. Only in one case the pain persisted up to month
18. Stimulation-related adverse effects experienced by pa-
tients were hoarseness, discomfort, sore throat, headache,
alteration of voice, and described as mild to moderate. In
one patient, hoarseness, sore throat and neck pain were
described as severe and intolerable, and the patient asked
to have the VNS generator switched off at 1 year; after
5 months we tried again to switch on the generator, but
she reported again intolerable side effects and 18 months
after the implant she asked to have the generator switched
off definitely. Pulse-width was not reduced, although this
strategy is commonly used to improve tolerability. No
(hypo) manic episodes, a rare but yet documented adverse
event potentially occurring with VNS, were observed dur-
ing the 60 months of stimulation.
Discussion
Our study shows that VNS effectiveness in a clinical
practice devoted to the care of individuals with TRD wasFigure 4 HDRS, MADRS and CGI-S scores across time for Patient 1 (f
comorbid diagnoses).comparable to the efficacy outcomes reported from prior
controlled and uncontrolled clinical trials: the 1-year re-
sponse and remission rates (based upon the HDRS-17)
were 40% and 40% respectively in our case series. Our
response rate at 1 year is comparable to the 31.8% re-
sponse rate (23.2 to 41.8%) after a mean of 20 weeks
found in a recent meta-analytical study [38].
To our knowledge, the present study is one of the few
prospective ones with a long (5-year for three patients)
follow-up of patients who underwent VNS implant for
TRD. Findings from our case series indicate a progres-
sive symptom reduction over the first year, although
statistical analyses were not significant; moreover, the
analysis of individual rating scales scores over time
shows that VNS, when effective (not in all patients), is
associated with a reduction of the number of depressive
recurrences. As already shown by previous reports
[21,22,36,39], the present 5-year follow-up study sug-
gests that VNS may prove more useful as a long-term
maintenance therapy for chronic depression rather thanemale, 66 years, Major Depressive Disorder, chronic MDE, no
Figure 5 HDRS, MADRS and CGI-S scores across time for Patient 2 (female, 51 years, Major Depressive Disorder, chronic MDE, no
comorbid diagnoses).
Albert et al. BMC Psychiatry  (2015) 15:64 Page 7 of 9for acute stabilization of an episode. Preliminary evi-
dence suggests that adjunctive VNS has two principal ef-
fects: first, it reduces depressive symptoms in a small
but significant proportion of patients who otherwise
would be unresponsive to standard treatments, and, sec-
ond, it reduces exacerbations over the long-term for the
vast majority of patients who responded to VNS addition
(sustained response) [40]. This long-term effect, how-
ever, appears from naturalistic studies or longitudinal
pivotal trials without a control or comparison group
[22,26,28,36]; long-term observations, being very few in
the literature, also small case series like the present one,
may be then of interest to clinicians.Table 3 Side effects of Vagus Nerve Stimulation
Side effects Sample
(N = 5)
Hoarseness, N (%) 4 (80.0)
Neck pain, N (%) 3 (60.0)
Sore throat, N (%) 2 (40.0)
Headache, N (%) 2 (40.0)
Paresthesia, N (%) 2 (40.0)
Anxiety, N (%) 1 (20.0)
Dysphagia- Dyspepsia, N (%) 1 (20.0)
Others (cough, dyspnoea, chest tightness, stridor, laryngism,
reflux, nausea, sweating, earache, snoring), N (%)
3 (60.0)Caution has to be used in interpreting our results, as
we observed no statistically significant changes in HDRS
or MADRS scores (nor in SF-36 scores) in the first
12 months of treatment (see Table 2); moreover, two pa-
tients dropped out by 12–18 months. Conclusions about
long-term effectiveness (and/or tolerability), being based
on the three subjects who remained on treatment, have
to be mitigated on the basis of these limitations.
VNS is not a procedure devoid of side effects; one pa-
tient from our case series was unable to tolerate hoarse-
ness, sore throat and neck pain, and the VNS generator
had to be switched off. Moreover, the majority of pa-
tients reported stimulation-related adverse effects, al-
though to a lesser degree. A careful screening of subjects
with TRD is then indicated, with particular attention not
only to the history of resistant depression (number of
previous failed antidepressant trials, compliance, etc.)
but also to the history of side effects of previous treat-
ments and to the ability of the patient to tolerate such
side effects. Unfortunately, we did not change stimula-
tion settings (e.g. reduced pulse-width) during the treat-
ment phase in order to counterbalance reported adverse
effects; we then acknowledge this as a limitation to be
kept in mind when interpreting our results concerning
side effects of VNS.
One patient refused to attend follow-up assessments
after 12 months of treatment, being depressive symp-
toms unchanged. We acknowledge that a 12-month
Albert et al. BMC Psychiatry  (2015) 15:64 Page 8 of 9VNS treatment may be too short to conclude that this
procedure is ineffective. Despite several efforts by the
psychiatrist in charge of that patient to maintain him in
the study, he withdrew the consent and dropped out. Al-
though it is unusual for someone to consent to having a
neurosurgical procedure and then refuse to be followed
up, he did so and told the psychiatrist that he was will-
ing to try transcranial magnetic stimulation at another
University hospital. This case underlines, to our opinion,
that a careful screening of subjects with treatment-resistant
mood disorders is compulsory before implementing neuro-
surgical procedures, with a particular attention to motiva-
tions to attend complex and expensive procedures such as
VNS implantation.
Conclusions
Our study, even though limited by its small sample size
and by its observational nature, shows that VNS may be
effective in clinical practice in a small but significant mi-
nority of patients. The investigation of potential predic-
tors of VNS response is strongly needed and future
studies in larger samples should focus on this matter.
Further long-term follow-up studies are also strongly
needed in order to confirm the putative stabilizing prop-
erty of VNS.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
UA participated in the design of the study, performed the statistical analysis
and drafted the manuscript. GM conceived of the study, participated in its
design and coordination, and critically revised the manuscript. AA and AV
participated in patients’ enrolment and follow-up. FB participated in the design
of the study and critically revised the manuscript. CF, AD and ML performed
neurosurgical procedures (VNS implantation) and revised the manuscript. ML
also participated in the design of the study and its coordination. All authors
read and approved the final manuscript.
Author details
1Rita Levi Montalcini Department of Neuroscience, Mood and Anxiety
Disorders Unit, University of Torino, via Cherasco 11, 10126 Turin, Italy. 2Rita
Levi Montalcini Department of Neuroscience, Neurosurgery Unit, University
of Torino, via Cherasco 11, 10126 Turin, Italy.
Received: 8 April 2014 Accepted: 9 March 2015
References
1. American Psychiatric Association. Diagnostic and statistical manual of
mental disorders (4th ed., Text Revision). Washington DC: American
Psychiatric Association; 2000.
2. Sackeim HA. The definition and meaning of treatment-resistant depression.
J Clin Psychiatry. 2001;62 suppl 16:10–7.
3. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, et al.
Evaluation of outcomes with citalopram for depression using measurement-based
care in STAR-D: implications for clinical practice. Am J Psychiatry. 2006;163:28–40.
4. Nemeroff CB. Prevalence and management of treatment-resistant depression.
J Clin Psychiatry. 2007;68(8):17–25.
5. Rush AJ, Marangell LB, Sackeim HA, George MS, Brannan SK, Davis SM, et al.
Vagus nerve stimulation for treatment-resistant depression: a randomized,
controlled acute phase trial. Biol Psychiatry. 2005;58:347–54.6. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D,
et al. Acute and longer-term outcomes in depressed outpatients requiring
one or several treatment steps: a STAR*D report. Am J Psychiatry.
2006;163:1905–17.
7. Berlim MT, Turecki G. Definition, assessment, and staging of treatment-resistant
refractory major depression: a review of current concepts and methods. Can J
Psychiatry. 2007;52(1):46–54.
8. Fekadu A, Wooderson SC, Markopoulou K, Cleare AJ. The Maudsley Staging
Method for treatment-resistant depression: prediction of longer-term outcome
and persistence of symptoms. J Clin Psychiatry. 2009;70(7):952–7.
9. Souery D, Papakostas GI, Trivedi MH. Treatment-resistant depression. J Clin
Psychiatry. 2006;67 suppl 6:16–22.
10. Wijeratne C, Sachdev P. Treatment-resistant depression: critique of current
approaches. Aust N Z J Psychiatry. 2008;42(9):751–62.
11. Kennedy SH, Giacobbe P, Rizvi SJ, Placenza FM, Nishikawa Y, Mayberg HS,
et al. Deep brain stimulation for treatment-resistant depression: follow-up
after 3 to 6 years. Am J Psychiatry. 2011;168:502–10.
12. Center for Devices and Radiological Health, Food and Drug Administration:
2005, Available at http://www.accessdata.fda.gov/cdrh_docs/pdf/
p970003s050a.pdf.
13. Schlaepfer TE, George MS, Mayberg H. WFSBP guidelines on brain
stimulation treatments in psychiatry. World J Biol Psychiatry. 2010;11:2–18.
14. Schachter SC, Schmidt D. Vagus Nerve Stimulation. London: Martin Dunitz;
2001.
15. Daban C, Matinez-Aran A, Cruz N, Vieta E. Safety and efficacy of vagus nerve
stimulation in treatment-resistant depression. A systematic review. J Affect
Disord. 2008;110:1–15.
16. Rush AJ, Siefert SE. Clinical issues in considering vagus nerve stimulation for
treatment-resistant depression. Exp Neurol. 2009;219:36–43.
17. Armitage R, Husain M, Hoffmann R, Rush AJ. The effects of vagus nerve
stimulation on sleep EEG in depression: a preliminary report. J Psychosom
Res. 2003;54(5):475–82.
18. Bajbouj M, Merkl A, Schlaepfer TE, Frick C, Zobel A, Maier W, et al. Two-year
outcome of vagus nerve stimulation in treatment-resistant depression. J Clin
Psychopharmacol. 2010;30:273–81.
19. Conway CR, Chibnall JT, Gangwani S, Mintun MA, Price JL, Hershey T, et al.
Pretreatment cerebral metabolic activity correlates with antidepressant
efficacy of vagus nerve stimulation in treatment resistant major depression:
a potential marker for response? J Affect Disord. 2012;139(3):283–90.
20. Corcoran CD, Thomas P, Phillips J, O’Keane V. Vagus nerve stimulation in chronic
treatment-resistant depression: preliminary findings of an open-label study. Br J
Psychiatry. 2006;189:282–3.
21. Cristancho P, Cristancho MA, Baltuch GH, Thase ME, O’Reardon JP. Effectiveness
and safety of vagus nerve stimulation for severe treatment-resistant major
depression in clinical practice after FDA approval: outcome at 1 year. J Clin
Psychiatry. 2011;72(10):1376–82.
22. Dell’Osso B, Oldani L, Palazzo MC, Balossi I, Ciabatti MT, Altamura AC. Vagus
nerve stimulation in treatment-resistant depression acute and follow-up results
of an Italian case series. J ECT. 2013;29:41–4.
23. George MS, Rush AJ, Marangell LB, Sackeim HA, Brannan SK, Davis SM, et al.
A one-year comparison of vagus nerve stimulation with treatment as usual
for treatment-resistant depression. Biol Psychiatry. 2005;58:364–73.
24. Kosel M, Brockmann H, Frick C, Zobel A, Schlaepfer TE. Chronic vagus nerve
stimulation for treatment-resistant depression increases regional cerebral
blood flow in the dorsolateral prefrontal cortex. Psychiatr Res.
2011;191(3):153–9.
25. Marangell LB, Rush AJ, George MS, Sackeim HA, Johnson CR, Husain MM,
et al. Vagus nerve stimulation (VNS) for major depressive episodes: one year
outcomes. Biol Psychiatry. 2002;51:280–7.
26. Nahas Z, Marangell LB, Husain MM, Rush AJ, Sackeim HA, Lisanby SH, et al.
Two-year outcome of vagus nerve stimulation (VNS) for treatment of major
depressive episodes. J Clin Psychiatry. 2005;66:1097–104.
27. Neuhaus AH, Luborzewski A, Rentzsch J, Brakemeier EL, Opgen-Rhein C,
Gallinat J, et al. P300 is enhanced in responders to vagus nerve stimulation
for treatment of major depressive disorder. J Affect Disord. 2007;100:123–8.
28. Nierenberg AA, Alpert JE, Gardner-Schuster EE, Seay S, Mischoulon D. Vagus
nerve stimulation: 2-year outcomes for bipolar versus unipolar treatment-resistant
depression. Biol Psychiatry. 2008;64:455–60.
29. Rush AJ, George MS, Sackeim HA, Marangell LB, Husain MM, Giller C, et al.
Vagus nerve stimulation (VNS) for treatment-resistant depression: a multicenter
study. Biol Psychiatry. 2000;47:276–86.
Albert et al. BMC Psychiatry  (2015) 15:64 Page 9 of 930. Rush AJ, Sackeim HA, Marangell LB, George MS, Brannan SK, Davis SM, et al.
Effects of 12 months of vagus nerve stimulation in treatment-resistant depression:
a naturalistic study. Biol Psychiatry. 2005;58:355–63.
31. Sackeim HA, Rush AJ, George MS, Marangell LB, Husain MM, Nahas Z, et al.
Vagus nerve stimulation (VNS) for treatment-resistant depression: efficacy,
side effects, and predictors of outcome. Neuropsychopharmacology.
2001;25:713–28.
32. Schlaepfer TE, Frick C, Zobel A, Maier W, Heuser I, Bajbouj M, et al. Vagus
nerve stimulation for depression: efficacy and safety in a European study.
Psychol Med. 2008;4:1–11.
33. Aaronson ST, Carpenter LL, Conway CR, Reimherr FW, Lisanby SH, Schwartz
TL, et al. Vagus nerve stimulation therapy randomized to different amounts
of electrical charge for treatment-resistant depression: acute and chronic
effects. Brain Stimul. 2013;6:631–40.
34. Christmas D, Steele JD, Tolomeo S, Sam Eljamel M, Matthews K. Vagus nerve
stimulation for chronic major depressive disorder: 12-month outcomes in
highly treatment-refractory patients. J Affect Disord. 2013;150:1221–5.
35. Yuan W, Williams BN. Long-term vagus nerve stimulation for severe refractory
depression: a case study with a six-year follow-up. J Neuropsychiatry Clin
Neurosci. 2012;24(4):E50–1.
36. Tisi G, Franzini A, Messina G, Savino M, Gambini O. Vagus nerve stimulation
therapy in treatment-resistant depression: a series report. Psychiatry Clin
Neurosci. 2014;68:606–11.
37. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview
for DSM-IV Axis I Disorders – Patient edition (SCID-I/P, Version 2.0). New
York: New York Psychiatric Institute, Biometrics Research Department; 1996.
38. Martin JLR, Martin-Sanchez E. Systematic review and meta-analysis of vagus
nerve stimulation in the treatment of depression: variable results based on
study designs. Eur Psychiatry. 2012;27:147–55.
39. Marangell LB, Suppes T, Zboyan HA, Prashad SJ, Fischer G, Snow D, et al. A
1-year pilot study of vagus nerve stimulation in treatment-resistant rapid-cycling
bipolar disorder. J Clin Psychiatry. 2008;69:183–9.
40. Lanotte MM, Albert U, Ducati A, Maina G. Vagus nerve stimulation in
resistant major depression. In: Lavano A, Landi A, Lanotte MM, editors.
Handbook of stereotactic and functional neurosurgery. Torino: Edizioni
Minerva Medica; 2011. p. 173–82.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
